iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2018. The requested “2017 Q4” period does not match this filing; this is an annual report covering fiscal 2018, with fiscal 2017 comparative information. Filed September 18, 2018.
Business Context
iBio is a biotechnology company focused on plant-based development and manufacturing of biotherapeutics. Its strategy combines contract development and manufacturing services through iBio CDMO, development of proprietary product candidates, and facility design and technology-transfer services.
The company operates a 139,000-square-foot facility in Bryan, Texas under a 34-year capital lease. Its lead proprietary candidate, IBIO-CFB03, is being advanced toward an Investigational New Drug application for fibrotic diseases, including systemic sclerosis and idiopathic pulmonary fibrosis. The company also entered commercial collaborations with CC-Pharming in China and ONEWAY Diagnostica in Brazil during fiscal 2018.
Financial Performance and Position
| Metric | FY2018 | FY2017 | Change |
|---|---|---|---|
| Revenue | $444,000 | $394,000 | +$50,000, approximately 13% |
| Research and development expense | $3.986 million | $4.117 million | -$131,000 |
| General and administrative expense | $10.685 million | $10.551 million | +$134,000 |
| Operating loss | $14.227 million | $14.274 million | Slightly improved |
| Consolidated net loss | $16.108 million | $16.139 million | Slightly improved |
| Net loss available to iBio stockholders | $16.365 million | $14.622 million | Higher loss after preferred dividends |
| Loss per share | $1.54 | $1.64 | Improved; reverse-split adjusted |
| Cash used in operating activities | $13.480 million | $13.163 million | Higher use of cash |
| Cash balance | $15.934 million | $8.088 million | +$7.846 million |
The filing does not report gross profit or gross margin. Revenue remained minimal relative to operating expenses, and the company remained deeply unprofitable. Approximate operating and net margins were highly negative because losses substantially exceeded revenue.
- Investing cash flow: $1.079 million used, including $934,000 for fixed assets and $145,000 for intangible assets.
- Financing cash flow: $22.406 million provided, primarily from equity and preferred-stock offerings, capital contributions, and related financing activity.
- Assets and equity: Total assets were $43.083 million; iBio stockholders’ equity was $16.166 million and total equity was $16.164 million.
- Accumulated deficit: $88.228 million at June 30, 2018.
- Lease obligation: $25.081 million, including $197,000 current and $24.884 million long term. The related capital lease carries annual base rent of approximately $2.1 million, subject to escalation and percentage-rent provisions.
Material Changes Versus Fiscal 2017
- Revenue increased modestly, primarily from third-party proof-of-concept, feasibility, and small-scale production contracts. No revenue was recognized under the Fiocruz amended agreement in fiscal 2018, compared with $137,000 in fiscal 2017.
- Research and development expense declined modestly, while general and administrative expense increased due largely to CDMO maintenance, utility, and personnel costs.
- Cash increased from $8.1 million to $15.9 million, but operating cash use increased to $13.5 million.
- The company completed a $4.5 million common-stock offering in November 2017 and a $16.0 million combined common-stock and convertible-preferred-stock offering in June 2018. The June offering was followed by an additional $1.35 million of gross proceeds from a partial over-allotment exercise on July 12, 2018.
- Common shares outstanding increased materially, and the June 2018 offering created potential conversion of approximately 13.4 million common shares from Series A and Series B preferred stock, subject to applicable limitations.
- The company completed a one-for-ten reverse stock split effective June 8, 2018. All share and per-share data in the filing are retrospectively adjusted.
- iBio increased its ownership of iBio CDMO to 99.99% in February 2017; fiscal 2018 therefore included only a nominal noncontrolling interest, compared with a materially larger noncontrolling-interest allocation in fiscal 2017.
Outlook, Risks, Contingencies and Unusual Items
Management expects continuing losses and negative operating cash flow while it develops the CDMO business, advances IBIO-CFB03, and pursues collaborations and technology-transfer opportunities. Based on cash on hand and expected funding, management stated that available resources were expected to support operations through at least September 30, 2019. This outlook depends on assumptions regarding future revenue, financing availability, and customer activity.
- Going concern: The company has a long history of losses, negative operating cash flow, and limited revenue. Management concluded that the June 2018 financing, subsequent over-allotment proceeds, and expected revenue provided adequate support for at least the next twelve months, but additional funding may be required thereafter.
- Financing and dilution: The company may use a Lincoln Park equity purchase agreement with up to approximately $14.9 million remaining available at June 30, 2018, subject to market-price and other conditions. Future equity issuance could materially dilute existing holders.
- Customer concentration: One customer represented more than 50% of fiscal 2018 revenue.
- CDMO execution: Results depend on attracting customers and achieving adequate facility utilization. Minimum percentage-rent obligations may adversely affect liquidity if sales remain below specified thresholds.
- Regulatory and development risk: No iBio therapeutic or vaccine product had received marketing approval. Most candidates remained in preclinical development, and IBIO-CFB03 still required IND-related work and subsequent clinical and regulatory milestones.
- Fraunhofer litigation: iBio is litigating alleged contractual breaches, technology-transfer failures, and related claims against Fraunhofer entities. The company prevailed on a threshold ownership issue but stated that the ultimate outcome and financial impact remain unpredictable.
- Listing compliance: NYSE American accepted a compliance plan through December 6, 2019 regarding stockholders’ equity and historical losses. The company resolved a separate low-share-price deficiency after the reverse stock split and returned to compliance on July 5, 2018.
- Related-party arrangements: The Bryan facility lease, certain expenses, and portions of the CDMO relationship involve affiliates of Eastern Capital Limited, a significant stockholder. Eastern’s beneficial ownership limitation was increased to 48% and standstill restrictions were extended through June 2020.
- Internal controls: Management reported effective disclosure controls and effective internal control over financial reporting; the smaller-reporting-company exemption meant the auditor did not provide an attestation report on internal controls.
Important Facts for Investors to Verify
- Whether CDMO customer contracts and the new China and Brazil collaborations generate material recurring revenue and improve facility utilization.
- The timing, funding, and regulatory status of the IBIO-CFB03 IND program and any subsequent clinical development.
- Cash burn, remaining availability under the Lincoln Park facility, and the timing and terms of any additional financing.
- The potential dilution from conversion of Series A and Series B preferred stock, outstanding options, and future equity sales.
- The financial exposure from the 34-year related-party capital lease, minimum rent and percentage-rent obligations, and related-party balances.
- Progress under the NYSE American compliance plan and the risk of future delisting proceedings.
- The status, expected costs, and potential recovery or liability associated with the Fraunhofer litigation.
- Whether the company’s revenue concentration and limited operating history create material collection, renewal, or customer-dependence risk.